Compounded semaglutide and tirzepatide price, October 2026: from $69 and $119 a month on one-year plans

It is a different product. Compounded semaglutide or tirzepatide is mixed by a compounding pharmacy from bulk ingredient; Wegovy and Zepbound are the FDA-approved drugs made by Novo Nordisk and Eli Lilly. The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and no compounded version has been through a clinical trial: the curves on this site come from STEP 1 and SURMOUNT-1, which tested the approved products.

The FDA has also warned that some compounded products use semaglutide sodium or semaglutide acetate, salt forms that are not the same active ingredient as the approved drug, and has received reports of dosing errors with compounded vials (FDA).

Only in a narrow form. Mass compounding was allowed while the drugs were on the FDA shortage list; the FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and the enforcement grace periods ended in spring 2025. A 503A pharmacy can still compound for one named patient when the prescriber documents a clinical reason the approved product will not work for that person; price is not a clinical reason.

Semaglutide or tirzepatide sold online as "research use only" or "not for human consumption" is not a legal prescription drug and must not be used in people; the FDA has sent warning letters to sellers of these products (FDA).

Compounded prices are set by each telehealth provider; the lowest we track is $69 a month on a one-year plan (billed $828/yr upfront, non-refundable), or $79 a month for the first 4 weeks for compounded semaglutide and $119 a month on a one-year plan (billed $1,428/yr upfront, non-refundable), or $129 a month for the first 4 weeks for compounded tirzepatide, visit included. Brand self-pay is $299–449 a month for Zepbound vials through LillyDirect and $349–399 for Wegovy pens through NovoCare Pharmacy, against a Wegovy list price of $1,349.02 per package. With commercial coverage the brand savings cards bring the copay to as little as $25. Price checked Oct 26, 2026 · joinem.co · joinem.co page 2 · joinem.co page 3 · joinem.co page 4; Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect; Oct 26, 2026 · novocare.com · novocare.com page 2

Compounded providers, by price

Each price shows the day it was last checked on the provider's own site. First month against later months: compounded tirzepatide price and compounded semaglutide price below; Wegovy at each dose: Wegovy cost by dose. Every compounded, brand-name and membership provider we track, by price →

Each price shows the date its provider's own page last confirmed it, with a link to that page; a price that could not be re-confirmed is shown as the last known price. We earn a commission from some providers; it never changes the order. How we make money

Compare payment options →

Brand-name routes

Zepbound vials are $299–449 a month self-pay through LillyDirect and Wegovy pens $349 through NovoCare Pharmacy, against a Wegovy list price of $1,349.02 per package; with commercial coverage the savings cards bring either to as little as $25. Every dose and route, with one-year totals and cost per pound, is on GLP-1 cost by route. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect; Oct 26, 2026 · novocare.com · novocare.com page 2

Each price shows the date it was last confirmed. Prices change often; the manufacturer or provider site is the final word. Every route side by side, with a cost-per-pound calculator, on GLP-1 cost by route. Claim refused? What to do when insurance won't cover Wegovy or Zepbound. On Medicare, check who qualifies for the Medicare GLP-1 Bridge before any compounded route.

Compounded tirzepatide is made by a compounding pharmacy, not Lilly, and has no FDA approval. Telehealth providers set the price, usually with the visit included. Some charge one price at every dose and others charge more at higher doses, so check the dose terms before you pay. What the first month costs against the months after, at the providers we track:

Price checked Oct 26, 2026 · joinem.co · joinem.co page 2; Unverified price, last read Oct 26, 2026 — confirm on SnagRx; Oct 26, 2026 · trytrimi.com; Last known price, Oct 17, 2026 — may have changed · confirm on HealthRX; Oct 25, 2026 · tryshed.com; Oct 25, 2026 · joinfound.com; Oct 26, 2026 · medgm.org; Oct 25, 2026 · raeliva.com

Availability depends on your state; every provider, with its terms, is in the provider table. Zepbound at each dose, for comparison: Zepbound cost by dose.

Compounded semaglutide has no FDA approval, and the FDA has warned about products made with semaglutide sodium or acetate, salt forms that are not the approved active ingredient. As with tirzepatide, providers set their own prices and dose terms:

Price checked Oct 26, 2026 · joinem.co · joinem.co page 2; Unverified price, last read Oct 26, 2026 — confirm on SnagRx; Oct 26, 2026 · trytrimi.com; Last known price, Oct 17, 2026 — may have changed · confirm on HealthRX; Oct 25, 2026 · tryshed.com; Oct 25, 2026 · joinfound.com; Oct 26, 2026 · medgm.org; Oct 25, 2026 · henrymeds.com; Oct 25, 2026 · raeliva.com

Availability depends on your state; every provider is in the provider table.

Per month, yes: compounded tirzepatide starts at $119/mo on a one-year plan, against $299–449 a month for Zepbound vials through LillyDirect. It is not the same product: compounded tirzepatide has no FDA approval and was not tested in SURMOUNT-1, so there is no cost per pound for it. With commercial coverage of Zepbound, the savings card at as little as $25 a month beats both. Compounded tirzepatide price by provider; Zepbound cost by dose. Price checked Oct 26, 2026 · joinem.co; Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

Because it is a different product with different costs behind it. A compounding pharmacy mixes tirzepatide from bulk ingredient for individual prescriptions; it has not paid for clinical trials, FDA review or the manufacturing controls an approved drug needs, and it does not price against a patent. That is also the risk: the FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, and the shortage exemption that allowed large-scale compounding of tirzepatide ended after December 19, 2024. The legal detail is above.

Ask which pharmacy fills the prescription, whether it is 503A or 503B, and whether it is licensed in your state. A 503A pharmacy compounds for a specific patient and is regulated mainly by its state board of pharmacy; a 503B outsourcing facility is FDA-registered and inspected, and the FDA publishes the list of registered outsourcing facilities. A pharmacy must be licensed in the state it ships to; your state board of pharmacy can confirm a license.

What is in the vial? Ask whether it is base semaglutide or a salt form, and for the certificate of analysis for your batch; the FDA has flagged semaglutide sodium and acetate as different active ingredients from the approved drug.

What happens if the pharmacy is told to stop? Titration takes months, and a supplier that disappears mid-titration leaves you restarting somewhere else. Ask for a live clinician you can reach about persistent vomiting, dehydration, or gallbladder or pancreas symptoms.

Anyone whose insurance covers Wegovy or Zepbound for weight management: with the savings card the approved drug can be $25 a month, below any compounded price. Anyone whose budget reaches $299 a month can buy the approved product self-pay. People who usually end up with compounded products have no coverage for weight-loss drugs and a budget under $299 a month. Check your route in three questions → Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect

Plan the switch rather than waiting it out: the shortage exemption that allowed mass compounding ended in 2025 (dates in the table above), the FDA followed with rounds of warning letters to telehealth sellers (more than 55 in September 2025, 30 more on March 3, 2026 and 25 in June 2026) and has proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list. What remains is a 503A pharmacy filling one patient's prescription for a documented individual reason, not routine monthly refills at scale. Where you restart is a prescriber's decision, made from three inputs, and the checklist below gives them those inputs.

The approved ladders, as written on the labels

These are the labeled schedules. Where you start is the next section.

Why there is no conversion chart, and why you should distrust any site that gives you one

Most compounded programs mirrored the Wegovy ladder: 0.25, 0.5, 1, 1.7, 2.4 mg. Some compressed it; some used increments on no approved label. Your vial's milligram number is one of three inputs to where you restart, and the weakest.

1. What was actually in the vial. Only semaglutide base is approved. Some compounded preparations used salt forms such as semaglutide sodium or acetate, never shown to deliver the same amount of drug. If your label names a salt form, no one can assume your exposure carries across.

2. Whether your schedule maps onto a labeled one. A compressed ladder or non-standard increment has no matching step on the approved label.

3. How long the gap has been. Tolerance to gastrointestinal side effects fades. After a few weeks off, a prescriber may step you back down, because the nausea comes back with the dose.

The clean case is Ozempic to Wegovy: same molecule, established content, and prescribers typically continue at the matching strength. Compounded to brand is not that case; the vial was never characterised like a labeled product.

Compounded semaglutide to Zepbound is not a conversion at all: different molecule, no mapping. The standard approach is to begin at 2.5 mg and titrate.

Don't pick your own number, and don't let a website pick it. Bring the facts below and let your prescriber decide. That is why this page has a checklist, not a chart.

What the approved versions cost

The price gap between compounded and brand-name has narrowed a lot since 2025. If cost was your only reason for compounded, rerun the numbers: every route from the savings card to list price, with one-year totals and cost per pound, is on GLP-1 cost by route, and Medicare's own path is on the Bridge page.

Bring this to the appointment

Seven things. They give the prescriber the three inputs above.

• A photo of the vial and its label — strength, salt form, and the pharmacy name
• Your actual weekly dose in milligrams, and how many weeks you were at it
• The date of your last dose. The one people forget, and it decides whether you step down
• Your side-effect history, particularly anything gastrointestinal, and what dose it appeared at
• Your starting weight and your current weight — run your curve and bring the chart
• Pen or vial preference. Some self-pay pricing applies only to the vial, which you draw up yourself
• Your insurance card, or a decision to pay cash, so the prescription goes to the right pharmacy first time

Some self-pay pricing applies only to the vial, which you draw up yourself; bring a pen-or-vial preference too.

Common questions about the switch

Do I have to restart at 0.25 mg? Not necessarily. Restarting low is the conservative default, not a rule. It depends on the three factors above, especially the gap since your last dose.

Can I keep taking a compounded version? Only narrowly: patient-specific compounding at a 503A pharmacy stays legal for a documented individual clinical need. Routine high-volume supply, which most telehealth programs ran on, is ending; the providers linked on this page, Embody, SnagRx, Collective, CoreAge Rx, HealthRX and MEDGm, are among the ones whose posted prices we check each week (paid affiliate links).

Will I regain weight during the gap? Some, usually. How much and how fast is covered on the stopping and regain page.

Will the approved version feel different? It can. Approved products have established content, so if your compounded preparation under- or over-delivered, side effects may shift. What to expect, week by week.

I was doing fine and now I have to change everything. Is my progress gone? No. A transition gap is a pause, not a reset. Compare a stall against the trial curve on the plateau page.

• Shortage status and compounding deadlines: FDA, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (page updated April 1, 2026): tirzepatide shortage resolved Dec 19, 2024 (503A discretion ended Feb 18, 2025; 503B Mar 19, 2025); semaglutide shortage resolved Feb 21, 2025 (503A Apr 22, 2025; 503B May 22, 2025).
• Not FDA-approved; salt forms; dosing errors: FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss.
• 503B bulks list proposal: Federal Register, List of bulk drug substances for which there is a clinical need under section 503B, May 1, 2026.
• Warning letters: FDA, warning letters database; example: Curex, Sept 9, 2025.
• 503B registered facilities: FDA, registered outsourcing facilities.
• Brand prices: Eli Lilly, Zepbound vial pricing, Dec 1, 2025 ($299 / $399 / $449; savings card as little as $25); NovoCare Pharmacy, Wegovy pricing ($349 / $399), and Novo Nordisk, Wegovy list price $1,349.02 and $25 savings card, both read 2026-09-20. Last known price, Oct 7, 2026 — may have changed · confirm on LillyDirect; Oct 26, 2026 · novocare.com · novocare.com page 2
• Compounded prices: each provider's own pricing pages, read 2026-09-24; the date for each row is in the compounded price table. Month-to-month prices are shown first, and prepay prices only with their terms. Linked providers: HealthRX (its pricing page) and MEDGm (its product pages).
• Switching from a compounded product: FDA announcements of warning letters to telehealth companies (September 2025, March 3, 2026, June 2026); the FDA proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (Federal Register, docket FDA-2018-N-3240, April 30, 2026); the current prescribing information for Wegovy, Ozempic, Zepbound and Foundayo.
• Trial data behind this site: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022).